DelveInsight’s “Ovarian Cancer Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Ovarian Cancer Overview
Ovarian cancer is a type of cancer that begins in the ovaries. The ovaries — each about the size of an almond — produce eggs (ova) as well as the hormones estrogen and progesterone. Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue.
Ovarian Cancer Epidemiology Insights
As per the data given by the Surveillance, Epidemiology, and End Results (SEER) Program (2022), an estimated 19,880 cases of ovarian cancer to be recorded in the year 2022. The program also estimated a rate of 10.6 per 100,000 women per year with new cases of ovarian cancer (based on 2015–2019 cases). There were also an estimated 233,565 women living with ovarian cancer in 2019.
According to statistics provided by the European Cancer Information System (ECIS) (2020), in 2020, there were about 7,162, 5,320, 5,370, 3,513, and 6,056 cases of ovarian cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively.
Click here to learn more about the Ovarian Cancer Market Landscape
The Report Covers the Ovarian Cancer Epidemiology Segmented by:
Ovarian Cancer diagnosed incident cases
Total Ovarian Cancer type-specific cases
Total Ovarian Cancer stage-specific cases
Total Ovarian Cancer Line wise treated cases
Ovarian Cancer Market Outlook
The treatment goal of ovarian cancer usually is to kill the cancer cells or remove the tumor so that the cancerous cells don’t metastasize and to prevent the recurrence of cancer and slow down growth. Sometimes the aim is to treat the symptoms in case of incurable cases by using chemotherapy, radiation, hormonal therapies, targeted drugs or a combination of any of these as per the requirement. In the case of early-stage ovarian cancer, surgery is performed to remove the tumor and stage cancer followed by chemotherapy to prevent the recurrence of ovarian cancer or to shrink the tumor if the tumor could not be removed by surgery. The aim is to increase the survival rate. In advanced stages of cancer (Stage III and IV) the focus is to put the tumor into remission so that it shrinks or disappears. In the case of cancer relapse, Chemotherapy is again used as a treatment option.
At present, Avastin (bevacizumab; Genentech), Zejula (niraparib; GlaxoSmithKline), Rubraca (rucaparib; Clovis Oncology), Lynparza (AstraZeneca), are a few approved drug therapies for the treatment of Ovarian Cancer. Rubraca (Clovis Oncology), Zejula (niraparib; GlaxoSmithKline), and Lynparza (olaparib; AstraZeneca), are poly (ADP-ribose) polymerase (PARP) inhibitors indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Key Companies Working in the Ovarian Cancer Market
AbbVie
Green 3 Bio Inc
Sanofi
AstraZeneca
And many others
Ovarian Cancer Therapies Covered and Analyzed in the Report:
Veliparib
Carboplatin
Olaparib
Bevacizumab
Learn more about the Key Companies and Emerging Therapies in the Ovarian Cancer Market
Table of Contents
Key Insights
Ovarian Cancer Introduction
Executive Summary of Ovarian Cancer
Disease Background and Overview
Epidemiology and patient population
Ovarian Cancer Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Ovarian Cancer Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services